A Phase II Clinical Trial of Cediranib and Olaparib Maintenance in Advanced Recurrent Cervical Cancer
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
COMICE is a randomised, double blind placebo controlled Phase II trial. The trial is
recruiting 108 patients with advanced recurrent cervical cancer who have completed their 1st
line chemotherapy for advanced/recurrent disease. Patients will be randomised to either
placebo Cediranib and Olaparib or active Cediranib and Olaparib and will remain on treatment
until progression of disease, unacceptable toxicity or withdrawal of consent. Patients will
be assessed for disease progression every 8 weeks through CT/MRI imaging. The primary end
point is Progression Free Survival.
Phase:
Phase 2
Details
Lead Sponsor:
The Clatterbridge Cancer Centre NHS Foundation Trust